SCHEMBL9070537

SCHEMBL9070537

CC1=CC(C)(C)N(Cc2ccccc2)c2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.51
NPSR1 Q6W5P4 3/20 0.49
LMNA P02545 3/20 0.49
TSHR P16473 2/20 0.49
USP2 O75604 1/20 0.49
MAPK1 P28482 1/20 0.49
MAPT P10636 3/20 0.46
KDM4E B2RXH2 2/20 0.46
KMT2A Q03164 2/20 0.46
MCOLN3 Q8TDD5 1/20 0.44
GAA P10253 1/20 0.42
AMPD2 Q01433 3/20 0.41
ALDH2 P05091 1/20 0.38
CHRM1 P11229 1/20 0.38
CES1 P23141 1/20 0.38
ALDH3A1 P30838 1/20 0.38
ELANE P08246 1/20 0.38
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13925442 0.89 ALDH1A1 (0.48) ALDH1A1NPSR1LMNATSHRUSP2
SCHEMBL15702659 0.86 ALDH1A1 (0.48) ALDH1A1NPSR1LMNATSHRUSP2
SCHEMBL15702596 0.83 MDM2 (0.47) ALDH1A1NPSR1LMNATSHRUSP2
SCHEMBL7879104 0.83 LMNA (0.54) ALDH1A1NPSR1LMNATSHRUSP2
SCHEMBL11076148 0.83 LMNA (0.54) ALDH1A1NPSR1LMNATSHRUSP2
SCHEMBL9166728 0.81 LMNA (0.53) ALDH1A1NPSR1LMNATSHRUSP2
SCHEMBL29638140 0.81 LMNA (0.53) ALDH1A1NPSR1LMNATSHRUSP2
SCHEMBL21160461 0.77 LMNA (0.53) ALDH1A1NPSR1LMNATSHRUSP2
SCHEMBL9163104 0.77 AMPD2 (0.37) ALDH1A1NPSR1LMNATSHRUSP2
SCHEMBL9074053 0.76 LMNA (0.48) ALDH1A1NPSR1LMNATSHRUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5547727-A RADIATION TRANSPARENT SUBSTRATE WITH RECORDING AND REFLECTION LAYERS WITH DYES OF CATIONIC AZOCYANINE DYES EASTMAN KODAK COMPANY (US) 1996-08-20 US claimed
EP-0717402-A2 Optical recording elements having recording layers containing cationic azo dyes EASTMAN KODAK COMPANY (US) 1996-06-19 EP claimed
US-20090036484-A1 Use of Unsaturated Quionoline or Naphtalene Derivatives as Medicaments ASTRAZENECA AB (SE) 2009-02-05 US disclosed
US-20090036484-A1 Use of Unsaturated Quionoline or Naphtalene Derivatives as Medicaments ASTRAZENECA AB (SE) 2009-02-05 US disclosed
US-5547727-A RADIATION TRANSPARENT SUBSTRATE WITH RECORDING AND REFLECTION LAYERS WITH DYES OF CATIONIC AZOCYANINE DYES EASTMAN KODAK COMPANY (US) 1996-08-20 US disclosed
EP-0717402-A2 Optical recording elements having recording layers containing cationic azo dyes EASTMAN KODAK COMPANY (US) 1996-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036484-A1 Use of Unsaturated Quionoline or Naphtalene Derivatives as Medicaments NR3C1, NR3C2, NR5A1 ALDH1A1 1475/4885NPSR1 33/4885LMNA 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.